Cancer immunotherpay

January 3, 2018

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Geldanamycin, 5-Azacitidine, Temozolomide, Cerivastatin, Salinomycin, &, Fluoxetine (GATCSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 3/January/2018, 9.23 am

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Geldanamycin, 5-Azacitidine, Temozolomide, Cerivastatin, Salinomycin, &, Fluoxetine (GATCSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 3/January/2018, 9.23 am https://genomediscovery.org/wp-content/uploads/2018/01/GATCSF-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-and-thereby-increases-the-efficacy-of-cancer-immunotherapy1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/GATCSF-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-and-thereby-increases-the-efficacy-of-cancer-immunotherapy1.jpg January 3, 2018 January 16, 2018

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

December 23, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Pravastatin, Herbimycin, Temozolomide, Zebularine, Salinomycin, and Clomipiramine (PHTZSC) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/December/2017, 12.42 am

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Pravastatin, Herbimycin, Temozolomide, Zebularine, Salinomycin, and Clomipiramine (PHTZSC) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/December/2017, 12.42 am https://genomediscovery.org/wp-content/uploads/2017/12/PHTZSC-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules-and-thereby-inhibits-GBM-progression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/PHTZSC-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules-and-thereby-inhibits-GBM-progression.jpg December 23, 2017 December 23, 2017

December 23, 2017

Natural product-derived therapy for enhancing anti-cancer immunity: Nimbolide, isolated from Neem (Azadirachta Indica), decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 24/December/2017, 12.35 am

Natural product-derived therapy for enhancing anti-cancer immunity: Nimbolide, isolated from Neem (Azadirachta Indica), decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 24/December/2017, 12.35 am https://genomediscovery.org/wp-content/uploads/2017/12/Nimbolide-increases-Cytotoxic-T-cell-and-B-cell-activity-enhances-anti-tumor-immunity-and-efficacy-through-down-regulation-of-LATS1-and-LATS2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/Nimbolide-increases-Cytotoxic-T-cell-and-B-cell-activity-enhances-anti-tumor-immunity-and-efficacy-through-down-regulation-of-LATS1-and-LATS2.jpg December 23, 2017 December 23, 2017

Introduction: What they say: A study from the Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA shows that “The Hippo Pathway Kinases LATS1/2…

December 19, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Macbecin, Temozolomide, EGCG, Salinomycin, Fluvastatin, Forodesine and Chloroquine (MTESFFC) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 19/December/2017, 10.02 pm

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Macbecin, Temozolomide, EGCG, Salinomycin, Fluvastatin, Forodesine and Chloroquine (MTESFFC) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 19/December/2017, 10.02 pm https://genomediscovery.org/wp-content/uploads/2017/12/MTESFFC-inhibits-the-expression-of-EGFR-and-Bcl2-xl-inhibits-a-number-of-immune-evasion-molecules-and-enhances-the-efficacy-of-cancer-immunotherapy.jpg1_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/MTESFFC-inhibits-the-expression-of-EGFR-and-Bcl2-xl-inhibits-a-number-of-immune-evasion-molecules-and-enhances-the-efficacy-of-cancer-immunotherapy.jpg1_.jpg December 19, 2017 December 19, 2017

December 15, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 15/December/2017, 11.23 pm

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 15/December/2017, 11.23 pm https://genomediscovery.org/wp-content/uploads/2017/12/GDESSF-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/GDESSF-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules.jpg December 15, 2017 December 15, 2017

December 8, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Desipramine, Evodiamine, Atorvastatin, Hypericin, Salinomycin and Temozolomide (DEAHSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 8/December/2017, 10.24 pm

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Desipramine, Evodiamine, Atorvastatin, Hypericin, Salinomycin and Temozolomide (DEAHSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 8/December/2017, 10.24 pm https://genomediscovery.org/wp-content/uploads/2017/12/Despiramine-Evodiamine-Atorvastatin-Hypercin-Salinomycin-and-Temozolomide-DEAHSAT-inhibit-the-expression-of-EGFR-and-Bcl2-xl-increase-p53-protein-levels-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/Despiramine-Evodiamine-Atorvastatin-Hypercin-Salinomycin-and-Temozolomide-DEAHSAT-inhibit-the-expression-of-EGFR-and-Bcl2-xl-increase-p53-protein-levels-1.jpg December 8, 2017 December 9, 2017

Popular Post